128 related articles for article (PubMed ID: 29758924)
1. The roles of CD133 expression in the patients with non-small cell lung cancer.
Wang D; Wen GM; Hou W; Xia P
Cancer Biomark; 2018; 22(3):385-394. PubMed ID: 29758924
[TBL] [Abstract][Full Text] [Related]
2. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
Le H; Zeng F; Xu L; Liu X; Huang Y
Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of cancer stem cell marker CD133 expression in non-small cell lung cancer: a systematic review.
Qu H; Li R; Liu Z; Zhang J; Luo R
Int J Clin Exp Pathol; 2013; 6(11):2644-50. PubMed ID: 24228135
[TBL] [Abstract][Full Text] [Related]
4. Polymorphisms of the stem cell marker gene
Liu QF; Zhang ZF; Hou GJ; Yang GY; He Y
BMJ Open; 2017 Aug; 7(8):e016913. PubMed ID: 28827262
[TBL] [Abstract][Full Text] [Related]
5. CXCR4 is involved in CD133-induced EMT in non-small cell lung cancer.
Tu Z; Xie S; Xiong M; Liu Y; Yang X; Tembo KM; Huang J; Hu W; Huang X; Pan S; Liu P; Altaf E; Kang G; Xiong J; Zhang Q
Int J Oncol; 2017 Feb; 50(2):505-514. PubMed ID: 28000861
[TBL] [Abstract][Full Text] [Related]
6. Predictive and prognostic effect of CD133 and cancer-testis antigens in stage Ib-IIIA non-small cell lung cancer.
Su C; Xu Y; Li X; Ren S; Zhao C; Hou L; Ye Z; Zhou C
Int J Clin Exp Pathol; 2015; 8(5):5509-18. PubMed ID: 26191258
[TBL] [Abstract][Full Text] [Related]
7. The Prognostic Effect of MAC30 Expression on Patients With Non-Small Cell Lung Cancer Receiving Adjuvant Chemotherapy.
Ding H; Gui X; Lin X; Chen R; Ma T; Sheng Y; Cai H; Fen Y
Technol Cancer Res Treat; 2017 Oct; 16(5):645-653. PubMed ID: 27688262
[TBL] [Abstract][Full Text] [Related]
8. A meta-analysis for CXCR4 as a prognostic marker and potential drug target in non-small cell lung cancer.
Zhang C; Li J; Han Y; Jiang J
Drug Des Devel Ther; 2015; 9():3267-78. PubMed ID: 26150700
[TBL] [Abstract][Full Text] [Related]
9. Prognostic impact of cancer stem cell-related markers in non-small cell lung cancer patients treated with induction chemoradiotherapy.
Shien K; Toyooka S; Ichimura K; Soh J; Furukawa M; Maki Y; Muraoka T; Tanaka N; Ueno T; Asano H; Tsukuda K; Yamane M; Oto T; Kiura K; Miyoshi S
Lung Cancer; 2012 Jul; 77(1):162-7. PubMed ID: 22387005
[TBL] [Abstract][Full Text] [Related]
10. Increased high-mobility group A2 correlates with lymph node metastasis and prognosis of non-small cell lung cancer.
Guo X; Shi J; Wen Y; Li M; Li Q; Li X; Li J
Cancer Biomark; 2018 Feb; 21(3):547-555. PubMed ID: 29278873
[TBL] [Abstract][Full Text] [Related]
11. High CD133 expression in the nucleus and cytoplasm predicts poor prognosis in non-small cell lung cancer.
Huang M; Zhu H; Feng J; Ni S; Huang J
Dis Markers; 2015; 2015():986095. PubMed ID: 25691807
[TBL] [Abstract][Full Text] [Related]
12. The combination of stem cell markers CD133 and ABCG2 predicts relapse in stage I non-small cell lung carcinomas.
Li F; Zeng H; Ying K
Med Oncol; 2011 Dec; 28(4):1458-62. PubMed ID: 20717756
[TBL] [Abstract][Full Text] [Related]
13. Is CD133 expression a prognostic biomarker of non-small-cell lung cancer? A systematic review and meta-analysis.
Wu H; Qi XW; Yan GN; Zhang QB; Xu C; Bian XW
PLoS One; 2014; 9(6):e100168. PubMed ID: 24940615
[TBL] [Abstract][Full Text] [Related]
14. The prognostic value of CSCs biomarker CD133 in NSCLC: a meta-analysis.
Chen E; Zeng Z; Bai B; Zhu J; Song Z
Oncotarget; 2016 Aug; 7(35):56526-56539. PubMed ID: 27489355
[TBL] [Abstract][Full Text] [Related]
15. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients.
Salnikov AV; Gladkich J; Moldenhauer G; Volm M; Mattern J; Herr I
Int J Cancer; 2010 Feb; 126(4):950-8. PubMed ID: 19676044
[TBL] [Abstract][Full Text] [Related]
16. Hyperphosphorylation of ribosomal protein S6 predicts unfavorable clinical survival in non-small cell lung cancer.
Chen B; Tan Z; Gao J; Wu W; Liu L; Jin W; Cao Y; Zhao S; Zhang W; Qiu Z; Liu D; Mo X; Li W
J Exp Clin Cancer Res; 2015 Oct; 34():126. PubMed ID: 26490682
[TBL] [Abstract][Full Text] [Related]
17. Prognostic role of B7-H4 in patients with non-small cell lung cancer: A meta-analysis.
Tan Z; Shen W
Oncotarget; 2017 Apr; 8(16):27137-27144. PubMed ID: 28404927
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of Transglutaminase 2 in non-small cell lung cancer patients.
Chihong Z; Yutian L; Danying W; Ruibin J; Huaying S; Linhui G; Jianguo F
Oncotarget; 2017 Jul; 8(28):45577-45584. PubMed ID: 28715877
[TBL] [Abstract][Full Text] [Related]
19. B7-H3 and CD133 expression in non-small cell lung cancer and correlation with clinicopathologic factors and prognosis.
Xu YH; Zhang GB; Wang JM; Hu HC
Saudi Med J; 2010 Sep; 31(9):980-6. PubMed ID: 20844808
[TBL] [Abstract][Full Text] [Related]
20. Overexpressed LAPTM4B-35 is a risk factor for cancer recurrence and poor prognosis in non-small-cell lung cancer.
Kong F; Gao F; Chen J; Sun Y; Zhang Y; Liu H; Li X; Yang P; Zheng R; Liu G; Jia Y
Oncotarget; 2016 Aug; 7(35):56193-56199. PubMed ID: 27486880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
